Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC)

Treatment of lung cancer: will financial issues become a criterion of choice?

“…Other studies compared erlotinib with chemotherapeutic agents such as docetaxel and pemetrexed. Carlson et al showed that erlotinib dominated the other two products [23]. Lewis et al compared erlotinib with docetaxel in a cost-utility study.…”

Early economic evaluation ot technologies for emerging interventions to personalize breast cancer treatment

“…The dose of drug (regimens) administered is widely optimized to be as high as possible while having acceptable toxicity for a large population. This results in the under-treatment of some patients, whereas other patients develop unacceptable toxicity [58][59][60][61].…”

“…Groot Koerkamp et al [55] 4 previously presented an EVSI application in a diagnostic procedure, but most EVSI analyses are applied to treatment interventions. Enhancing the literature on the expected value of further information about diagnostics is relevant for manufacturers, because current regulations incentivize research and development of diagnostics relatively poorly [59]. In the meantime, EVSI examples can illustrate how diagnostics' R&D can be steered more efficiently to increase the returns on investments from a healthcare and societal perspective.…”

“…Conjoint analysis Reveals trends in consumer preferences for competing products by presenting them as bundles of attributes [84].…”

“…Canada [48] due to the lack of a Dutch estimator, NHS reference costs [27,41,[49][50][51][52][53][54][55][56] and average selling prices from CMS [28] and literature [57][58][59][60][61][62][63] for the US. All costs were inflated to 2013 values using the Consumer Price Index [64] and transformed to Euros [65].…”